Background With the advent of the direct-acting antiviral agents, significant drug-drug interaction (DDI) potential now exists for patients treated for chronic hepatitis C virus (HCV) infection. However, little is known about how often patients with HCV infection use medications that may interact with newer HCV treatments, especially those with cytochrome P450 3A (CYP3A) DDI potential.
Background With the advent of the direct-acting antiviral agents, significant drug-drug interaction (DDI) potential now exists for patients treated for chronic hepatitis C virus (HCV) infection. However, little is known about how often patients with HCV infection use medications that may interact with newer HCV treatments, especially those with cytochrome P450 3A (CYP3A) DDI potential.
Methods Using a large US commercial insurance database, medication use and comorbidity burden were examined among adult patients with a chronic HCV diagnosis from 2006 to 2010. Medications were examined in terms of total number of prescription claims, proportion of patients exposed, and DDI potential with the prototypical CYP3A direct-acting antiviral agents boceprevir and telaprevir, for which data were available.
Results Patient comorbidity burden was high and increased over the study period. Medication use was investigated in 53 461 patients with chronic HCV. Twentyone (53%) of the top 40 most utilized medications were classified as having interaction potential, with 62% of patients receiving at least one of the top 22 interacting medications by exposure. Of these, 59 and 41% were listed in a common DDI resource but not in medicationprescribing information, 77 and 77% had not been investigated in DDI studies, 41 and 36% did not have clear recommendations for DDI management, and only 14 and 23% carried a recommendation to avoid coadministration for boceprevir and telaprevir, respectively.
Introduction
Chronic hepatitis C virus (HCV) infection affects an estimated 3.2 million people in the USA, whereas in the European Union, HCV affects ∼ 8.1 million people and contributes to one-third of deaths among patients with cirrhosis or liver cancer [1] [2] [3] . The introduction of directacting antiviral agents (DAAs), beginning with telaprevir and boceprevir in 2011, has revolutionized the treatment of genotype 1 chronic HCV infections by improving rates of sustained virologic response markedly in conjunction with peginterferon and ribavirin (triple therapy) [4] . Currently, there are three classes of DAAs that target different steps in the viral replication cycle: NS3/4A protease inhibitors, NS5B polymerase inhibitors, and NS5A inhibitors. Despite advantages in improving virologic response, many of these new DAAs also carry high drug-drug interaction (DDI) potential because of their metabolism by cytochrome P450 3A (CYP3A) or transport by P-glycoprotein (P-gp) [5] .
A number of DDI studies on DAAs have been conducted in both healthy volunteers and diseased populations [6] [7] [8] [9] , with a focus on medications that have the potential for significant drug interaction or that may be highly utilized in certain patient populations [6, 10, 11] . Recent review articles have provided some guidance for the clinical management of DDIs using NS3/4A protease inhibitors telaprevir and boceprevir on the basis of a composite of available literature and theoretical considerations of their clinical pharmacology [5, [12] [13] [14] [15] . However, there is a paucity of information on their actual DDI risk in the outpatient setting. Recently, DDI risk with initiation of NS3/4A protease inhibitor therapy was determined to be substantial for about one-half of a small cohort of German HCV patients at a tertiary referral center [16] . Knowledge of the medication use patterns in a larger heterogeneous population would add vital insight to our understanding of the potential for interactions with current and emerging agents [5, 13] .
The primary objective of this study was to characterize medication utilization in a representative chronic HCV population. Specific aims included: (i) to assess the most highly utilized medications from 2006 to 2010 by prescription claims and by exposure and (ii) to evaluate the telaprevir and boceprevir DDI potential of highly utilized medications in patients with HCV. To provide a context for interpretation of the medication use data, comorbidities and other demographic and clinical characteristics of the patients with chronic HCV also were explored. The DDI risk for boceprevir and telaprevir, prototypical CYP3A-metabolized DAAs, will be similar to the DDI risk for other DAAs that are substrates or inhibitors of CYP3A such as simeprevir, faldaprevir, or daclatasvir, and especially for DAAs that will be coadministered with ritonavir to inhibit their CYP3A-dependent metabolism (ABT-450 and danoprevir). These agents will soon be used extensively in patients with HCV throughout the world.
Materials and methods

Study population and data
A retrospective observational study design was adopted using the Truven Health Analytics Marketscan Commercial Claims and Encounters Research Database for the years 2006-2010. The database includes deidentified medical inpatient and outpatient claims, outpatient pharmaceutical claims, and enrollment data files and provides demographic information, medical diagnoses, healthcare procedures, and pharmacy claims for ∼ 20 million enrollees from over 100 nationwide US insurers.
Five different 1-year cross-sectional cohorts were constructed for each year from 2006 to 2010 to examine demographic characteristics, medication use, and comorbid health conditions in chronic HCV patients. Within each 1-year cross-section, patients were selected for inclusion if they (i) had at least one inpatient or two outpatient International Classification of Diseases, 9th edition (ICD-9), codes for chronic HCV (070.54 or 070.44) occurring on separate days, (ii) were 18 years of age or older, and (iii) had continuous enrollment for the entire 1-year period. This cohort was used to investigate demographic and clinical characteristics. A subcohort of these patients with prescription insurance benefits filling at least one prescription per year was further selected to examine concomitant medication use. This subcohort was identified to ensure adequate capture of prescription claims information. Given the prevalent cross-sectional nature of this study, patients could contribute to multiple cross-sections if they met the eligibility criteria for multiple years.
Demographic and clinical characteristics
To characterize patients with HCV who were eligible to receive telaprevir or boceprevir, information was captured for each 1-year calendar period including demographic information (age and sex), type of insurance coverage, and region of residence (e.g. Northeast, North Central, South, or West). In addition, comorbidities that were reported previously as highly prevalent in chronic HCV patients or were otherwise believed to be clinically relevant were identified for each 1-year cross-sectional cohort from either the inpatient or the outpatient files using compiled ICD-9 code definitions from the medical literature (Appendix A) [17, 18] . Compensated cirrhosis was defined directly by ICD-9 code definition; advanced liver disease was a composite definition representing decompensated disease and included codes for ascites, spontaneous bacterial peritonitis, hepatic encephalopathy, portal hypertension, esophageal varices, hepatorenal syndrome, or hepatocellular carcinoma. The Charlson Comorbidity Index, a general measure of comorbidity and predicted mortality, was calculated for each 1-year cross-sectional cohort [19, 20] .
Medication use
Medication use was characterized among the subcohort of chronic HCV patients with prescription insurance benefits. Prescription drug use was identified through national drug codes in the outpatient pharmaceutical files merged with the REDBOOK supplement, which identifies specific medications and therapeutic categories. As the standard of care during the study period was dual therapy with interferon and ribavirin, a 'treated' patient was defined as having one or more prescription claims for ribavirin plus one or more prescription claims for peginterferon α-2a/2b or interferon alfacon-1 during each 1-year eligible calendar period. The average number of distinct medications per individual (drug name without regard to strength or form) was also calculated within the 1-year calendar period for eligible enrollees.
Drug-drug interaction potential
To identify highly utilized medications in the chronic HCV cohort, the 200 most commonly used medications were identified and ranked according to the total number of prescription claims. These medications were then assessed for their potential to interact with telaprevir or boceprevir using the University of Liverpool Hepatitis DDI website (as of September 2013), a recommended international resource by the American Association for the Study of Liver Diseases HCV treatment guidelines [21] . This resource was used, as prior data has suggested it is a more comprehensive resource than the prescribing information [22, 23] . Drug interactions with telaprevir and boceprevir are designated on this site as: 'should not be coadministered', 'potential interaction', or 'no clinically significant interaction expected' [21].
To identify the annual proportion of HCV patients exposed to medications with known telaprevir and boceprevir DDI potential, medications were selected from the Liverpool resource's printable charts (as of April 2013) if classified as either 'should not be coadministered' or 'potential interaction' [21] . For each of these medications, the proportion of patients with one or more outpatient prescription claims during each 1-year period of eligibility was determined. Medications were then ranked by average annual proportion of patients exposed within each 1-year cross-sectional cohort. Medications were queried by individual drug ingredients such that one query could span multiple products, identifying usage by total exposure rather than through individually marketed products. For example, codeine was not ranked in the top 40 medications by claims when comparing individual drug products, but its total population exposure was 8.9% across multiple drug products.
Medications with drug interaction potential in the Liverpool resources' complete recommendations were selected for subanalysis if they were listed as one of the top 40 most utilized medications by prescription claims or had high patient exposure. The prescribing information was compared with the Liverpool resource charts for the selected medications. Drug interaction details in the Liverpool resource were used to further analyze the proportion of these drugs with DDI potential formally investigated in studies, the proportion with clear and actionable recommendations for DDI management, and the proportion not recommended for coadministration. A recommendation for DDI management was considered clear and actionable if there was a statement advising an action such as avoiding, adjusting dose, monitoring, or therapeutic drug monitoring.
Statistical analysis
For each 1-year cross-sectional cohort, descriptive statistical analyses were carried out to assess each demographic and clinical characteristic, including the proportion of patients 'treated' with peginterferon and ribavirin and for comorbid conditions. An average from 2006 to 2010 across each characteristic was weighted by the total number of patients in each year. In addition, the annual proportions of patients using medications present in the top 200 drug list and those defined by our team as clinically relevant in the chronic HCV population were also described.
All analyses were carried out using SAS 9.2 (SAS Institute, Cary, North Carolina, USA). This study was approved by the Institutional Review Board of the University of North Carolina at Chapel Hill.
Results
Of 197 381 individuals aged 18 years or older with any HCV diagnosis during the study period, 71 584 patients (106 283 1-year cross-sections) were diagnosed with chronic HCV in at least one inpatient or two outpatient visits and maintained continuous enrollment for at least one 1-year period. Demographic and clinical comorbidity characteristics are reported in Table 1 . There were fewer eligible individuals in 2006 and 2007 relative to the successive years. The average overall age of the study sample was 51.2 7.5 years, with an increasing trend over the 5-year period from 49.7 years in 2006 to 52.4 years in 2010; 62.2% were male. The majority of the study patients resided in the Southern region of the USA (48.6%) and had a preferred provider organization insurance plan (65.7%). Comorbid conditions prevalent in at least 5% of patients (in order of decreasing prevalence) were hypertension, lipid metabolism disorders, compensated cirrhosis, advanced liver disease, type 2 diabetes, depression, nonalcoholic fatty liver disease, and chronic obstructive pulmonary disease/asthma. Prevalence increased over the study period for the majority of conditions queried, with the highest increases observed for obesity, hepatocellular carcinoma, and alcohol abuse/ dependence. The average rates of liver transplantation and HIV/AIDS in the cohort were 3.9 and 2.8%, respectively.
A subcohort of 53 461 individuals (79 185 cross-sections) had prescription insurance benefits and was followed to examine medication use patterns. HCV treatment rates and comorbidity measures for this subcohort are reported in Table 2 . On average, 31.2% of patients were classified as 'treated', having received both interferon and ribavirin. The mean Charlson Comorbidity Index score was 2.2 and increased over the study period; the average for the treated group was lower than that for the untreated group (1.9 vs. 2.4, respectively). The average number of unique medications filled per patient for the treated group was higher than that for the untreated group (11.5 vs. 8.9, respectively). none of the medications were classified as 'should not be coadministered' (0%), and two medications (5.0%) were not listed in the resource.
Of the 225 drugs listed in the Liverpool resource, 143 were categorized as 'potential interaction' or 'should not be coadministered' with boceprevir or telaprevir. Of these, 109 were selected for analysis if they had Food and Drug Administration approval during the study period and were not classified as having a drug-disease interaction. The medication with the highest exposure was zolpidem, which was used by 14.1% of the subcohort.
Medications showing increasing utilization over the study period included pravastatin, tenofovir, buprenorphine, simvastatin, amlodipine, tacrolimus, and prednisone; decreasing utilization was observed for escitalopram and venlafaxine. Simvastatin, which is contraindicated with telaprevir and boceprevir, showed a notable increase in utilization between 2006 and 2010.
Of the most utilized medications by prescription claims or exposure, a subset of 22 highly utilized medications was examined further. The Liverpool resource recommendations are summarized in Table 4 . For telaprevir, 13 (59.1%) were listed in the prescribing information, 14 (63.6%) carried a clear recommendation for DDI management, five (22.7%) carried a recommendation to avoid coadministration, and five (22.7%) were investigated formally in a DDI study. For boceprevir, nine (40.9%) were listed in the prescribing information, 13 (59.1%) carried a clear recommendation for DDI management, three (13.6%) carried a recommendation to avoid coadministration, and five (22.7%) were investigated formally in a DDI study. These 22 medications with drug interaction potential are listed by exposure in Table 5 . On average, 62.1% of chronic HCV patients were exposed to at least one of these 22 medications.
A complete listing of percentages using specific queried medications can be found in Appendix C, including rates of utilization for the medications with DDI potential.
Discussion
Medication utilization has been historically inferred from clinical knowledge or extracted from limited clinical trial data. To our knowledge, this is the first published systematic investigation of modern day clinical medication utilization in a large, real-world database of patients with chronic HCV. Previous studies have been smaller or have examined potential interactions within a strictly controlled setting. A 2011 analysis examined the use of certain comedications with boceprevir triple therapy in Drug interactions with protease inhibitors Lauffenburger et al. 1077
three major late-phase studies; however, patients with certain comorbidities were excluded, limiting the study's generalizability [10, [24] [25] [26] . Recently, Maasoumy et al.
[16] investigated DDI risk during initiation of HCV protease inhibitor therapy in 115 consecutively treated patients seen at a German tertiary referral center. They Bold indicates drug also listed in Table 3 . BOC, boceprevir; C, contraindicated; I, potential interaction; N, none; PI, prescribing information; TVR, telaprevir. Although the drug is classified as potential interaction, the recommendation is to avoid coadministration. Defined using a subcohort of chronic HCV patients with prescription drug benefits and filling at least one prescription per year.
reported that 38% of the 116 outpatient medications used in their cohort had DDI potential or unknown DDI risk and that 49% of patients were exposed to at least one drug with DDI potential during treatment. The four most frequently encountered medication classes in the German cohort included β-blockers, proton pump inhibitors, thyroid hormones, and dihydropyridine calcium channel blockers (e.g. amlodipine), and only 4% of encountered drugs were strictly contraindicated [16] . In contrast, in our large US cohort of chronic HCV patients (not restricted by treatment), the four most frequently used drug categories included analgesics/antipyretics and opiate agonists, antidepressants, antivirals, and gastrointestinal drugs including proton pump inhibitors. In our study, 58% of the top 40 outpatient medications had DDI potential or unknown DDI risk, and 62% of patients were exposed to at least one of the 22 most highly utilized medications with DDI potential. Medications with DDI potential used by greater than 9% of patients included zolpidem, alprazolam, amlodipine, and prednisone. On the basis of both studies, the DDI risk appears to be substantial among chronic HCV patients.
Our study also demonstrates increasingly high comorbidity burden in patients with chronic HCV, on the basis of rates of specific comorbidities, as well as the Charlson Comorbidity Index. A small cross-sectional retrospective study investigating comorbidities associated with HCV from 1998 to 2007 found that HIV/AIDS, renal disease, diabetes, and obesity were more prevalent in patients with HCV compared with the US population [27] . Higher comorbidity rates may reflect the selective age distribution of the HCV population, but there is also some recent evidence that comorbidity rates may be higher in the HCV population even after adjusting for age [17] . In our study, the potential increasing comorbidity rates may be related to the increasing average age of the underlying HCV population and may have implications for increasing polypharmacy and complexity of DDI assessment.
As a result, it is important that practitioners be familiar with current DDI management recommendations. However, as observed with approximately one-third of the drugs identified in this study, many potential DDIs have not been studied formally and thus clear and actionable DDI recommendations are often absent. For those DDIs that do provide actionable recommendations, DDI management depends upon the nature of the interaction. The most well characterized DDIs with telaprevir and boceprevir are those involving the inhibition or induction of oxidative metabolism by CYP3A. For simvastatin (the most highly utilized statin in this population, Appendix B), reasonable intervention options exist, including using a 'statin holiday' by removing medication for the duration of treatment, or stabilizing the patient on an alternative statin with lower interaction potential before therapy [28] . For other drugs such as salmeterol, fluticasone, or other inhaled corticosteroids, alternatives such as formoterol or beclomethasone may be used [5] . Comparatively, use of systemic corticosteroids may be unavoidable in some settings such as maintenance of immunosuppression in the transplant setting, and providers must weigh the risk of reduced efficacy of telaprevir and boceprevir due to the possible induction of CYP3A [5, 29, 30] . Management of depression-like symptoms during treatment with peginterferon-based therapies has been shown to affect treatment outcomes and often involves the use of antidepressants such as selective serotonin reuptake inhibitors [31] . Serotonin reuptake inhibitors are generally metabolized by multiple CYP450 enzymes with CYP3A providing only partial contribution, and therefore the risk for a clinically significant CYP3A-mediated DDI with DAAs is low [5, 14] . In addition, Sockalingam et al. [32] in a recent review of data from major clinical trials, investigating the neuropsychiatric adverse effects of DAAs, as well as DDIs between DAAs and psychiatric medications, concluded that DAAs have minimal neuropsychiatric risk. Opioids and other analgesics also are metabolized by multiple pathways including CYP3A, but they are often self-titrated by patients for pain control, complicating the risk for DDIs [33, 34] . In addition, they are often used in combination with acetaminophen, which may represent the greatest risk to patients because providers may not recognize the daily acetaminophen dose from all sources [35] .
Less characterized DDIs with boceprevir and telaprevir are those involving hepatic transport proteins [36] . Boceprevir appears to be an inhibitor of organic anion transporting polypeptide 1B (OATP1B), whereas telaprevir is an inhibitor of OATP1B1 and OATP1B3, organic cation transporter 1, and multidrug and toxin extrusion 1; these transporters are involved in the active uptake of drugs in the liver [36, 37] . Inhibition of these transporters may result in higher systemic exposure but reduced hepatic exposure and efficacy of drugs targeting the liver (e.g. statins, metformin, valsartan) [38] [39] [40] . Boceprevir also appears to be a substrate of breast cancer resistance protein (BCRP), a hepatic transporter involved in the active biliary elimination of drugs from the liver [37] . Drugs that are substrates/inhibitors of BCRP (e.g. eltrombopag and cyclosporine) may potentially inhibit the biliary elimination of boceprevir, resulting in higher hepatic exposure [41, 42] . Alternatively, boceprevir could increase the hepatotoxic potential of other coadministered BCRP substrates (e.g. methotrexate, rosuvastatin, lapatinib) [43] [44] [45] . Additional examination of the potential interactions involving elimination pathways mediated by hepatic transport proteins is needed.
Whereas many drug interactions are predicted from a theoretical understanding of the drug's clinical pharmacology, most are never investigated in DDI studies. Accordingly, at the time of this study, many drugs with theoretical DDI potential through CYP3A had not been formally investigated. Whereas it is impractical and cost-prohibitive to study every possible drug interaction in a formal DDI study, it is also imprudent to risk treatment failure or toxicity without a sound understanding of the DDI potential in a real-world setting. Theoretical prediction is limited by our scientific understanding, which is particularly evident with transporter interactions where the science is in its infancy. To mitigate risk, computer simulation with tools such as SimCyp should be considered before drug approval to complement formal in-vivo studies and establish a better framework for reliable DDI prediction [46, 47] . However, much of the DDI knowledge will still be derived from postmarketing studies and expert opinion, as demonstrated by the majority of interacting medications in this study that were listed in the Liverpool resource but not in the prescribing information. Here, DDI registries and pharmacovigilance algorithms may complement in-vivo studies in the detection of DDIs quickly and efficiently [21, 48] . As DDI information is discovered, the prescribing information will remain a reliable source of information about formal DDI studies that were performed by the pharmaceutical company, but resources that are comprehensive, regularly updated, and maintained by clinical experts, such as the Liverpool database, may provide a more optimal model for access to actionable DDI information [21] . The sensitivity and specificity of diseasespecific resources such as the Liverpool database also should be compared with other widely used, validated interaction checking software such as ePocrates [49] .
This study has several limitations. ICD-9 definitions, although applied from validated studies, may differ from other definitions such as the Clinical Classification Software from the US Agency for Healthcare Research and Quality; this may partially account for slight differences in comorbidity rates observed in other reports [17, 27] . Medication use was explored in the chronic HCV cohort and was not limited to treated patients; hence, conclusions should be drawn in this context. In addition, only outpatient medication claims were evaluated; hence, utilization rates may not appropriately estimate medications with use limited to hospital settings. Over-thecounter medications could not be evaluated in this database. This study also was restricted to insured HCV patients in the USA and may not be fully representative of the typical US HCV population [50] or populations in other parts of the world where treatment patterns and comorbidities may differ. However, this study is significant because it examined a wide range of potential prescription medications available both in the USA and worldwide for their interaction potential with boceprevir and telepravir, and this information was integrated with the actual exposure to these medications in a real-world setting.
Whereas the focus of this study was to inform DDI assessment for currently available agents, these findings may also have strong implications for other candidates in development. Two new DAAs, simeprevir and sofosbuvir, have been recently approved and others are in phase 3 evaluation for HCV treatment [51, 52] . An all-oral regimen utilizing a protease inhibitor boosted with ritonavir (ABT-450/r), combined with an NS5A inhibitor and a non-nucleoside polymerase will likely be licensed by the end of 2014. Moreover, faldaprevir and daclatasvir, which are currently undergoing approval in both the USA and in Europe, have been shown to be CYP3A substrates and require dose reductions when used in combination with a ritonavir-boosted antiretroviral [3, [53] [54] [55] . Thus, the information obtained from examining the first two prototypical CYP3A DAAs will remain highly relevant and applicable [56] . As knowledge increases with regard to the mechanism(s) and role(s) of metabolism and transport for various drugs, particularly in the setting of liver disease, the information provided here will become highly relevant.
